OBJECTIVES: Renal denervation (RDN) is a promising therapy for resistant hypertension. RDN is assumed to decrease sympathetic activity. Consequently, RDN can potentially increase renal oxygenation. Blood oxygen level-dependent MRI (BOLD-MRI) provides a non-invasive tool to determine renal oxygenation in humans. The aim of the current study was to investigate the effect of RDN on renal oxygenation as determined by BOLD-MRI. METHODS: Patients with resistant hypertension or the inability to follow a stable drug regimen due to unacceptable side effects were included. BOLD-MRI was performed before and 12 months after RDN. Twenty-seven patients were imaged on 3 T and 19 on 1.5 T clinical MRI systems. RESULTS: Fifty-four patients were included, 46 patients (23 men, mean age 57 years) completed the study. Mean 24-h BP changed from 163(±20)/98(±14) mmHg to 154(±22)/92(±13) mmHg (p = 0.001 and p < 0.001). eGFR did not change after RDN [77(±18) vs. 79(±20) mL/min/1.73 m(2); p = 0.13]. RDN did not affect renal oxygenation [1.5 T: cortical R2*: 12.5(±0.9) vs. 12.5(±0.9), p = 0.94; medullary R2*: 19.6(±1.7) vs. 19.3(1.4), p = 0.40; 3 T: cortical R2*: 18.1(±0.8) vs. 17.8(±1.2), p = 0.47; medullary R2*: 27.4(±1.9) vs. 26.7(±1.8), p = 0.19]. CONCLUSION: The current study shows that RDN does not lead to changes in renal oxygenation 1 year after RDN as determined by BOLD-MRI. KEY POINTS: • Renal denervation significantly decreased ambulatory blood pressure. • Renal denervation did not change renal oxygenation as determined by BOLD-MRI. • Absence of a change in renal oxygenation might be explained by autoregulation.
OBJECTIVES: Renal denervation (RDN) is a promising therapy for resistant hypertension. RDN is assumed to decrease sympathetic activity. Consequently, RDN can potentially increase renal oxygenation. Blood oxygen level-dependent MRI (BOLD-MRI) provides a non-invasive tool to determine renal oxygenation in humans. The aim of the current study was to investigate the effect of RDN on renal oxygenation as determined by BOLD-MRI. METHODS:Patients with resistant hypertension or the inability to follow a stable drug regimen due to unacceptable side effects were included. BOLD-MRI was performed before and 12 months after RDN. Twenty-seven patients were imaged on 3 T and 19 on 1.5 T clinical MRI systems. RESULTS: Fifty-four patients were included, 46 patients (23 men, mean age 57 years) completed the study. Mean 24-h BP changed from 163(±20)/98(±14) mmHg to 154(±22)/92(±13) mmHg (p = 0.001 and p < 0.001). eGFR did not change after RDN [77(±18) vs. 79(±20) mL/min/1.73 m(2); p = 0.13]. RDN did not affect renal oxygenation [1.5 T: cortical R2*: 12.5(±0.9) vs. 12.5(±0.9), p = 0.94; medullary R2*: 19.6(±1.7) vs. 19.3(1.4), p = 0.40; 3 T: cortical R2*: 18.1(±0.8) vs. 17.8(±1.2), p = 0.47; medullary R2*: 27.4(±1.9) vs. 26.7(±1.8), p = 0.19]. CONCLUSION: The current study shows that RDN does not lead to changes in renal oxygenation 1 year after RDN as determined by BOLD-MRI. KEY POINTS: • Renal denervation significantly decreased ambulatory blood pressure. • Renal denervation did not change renal oxygenation as determined by BOLD-MRI. • Absence of a change in renal oxygenation might be explained by autoregulation.
Authors: Felix Mahfoud; Bodo Cremers; Julia Janker; Britta Link; Oliver Vonend; Christian Ukena; Dominik Linz; Roland Schmieder; Lars Christian Rump; Ingrid Kindermann; Paul Andrew Sobotka; Henry Krum; Bruno Scheller; Markus Schlaich; Ulrich Laufs; Michael Böhm Journal: Hypertension Date: 2012-06-25 Impact factor: 10.190
Authors: Arjang Djamali; Elizabeth A Sadowski; Rebecca J Muehrer; Shannon Reese; Chanigan Smavatkul; Aparna Vidyasagar; Sean B Fain; Ryan C Lipscomb; Debra H Hullett; Millie Samaniego-Picota; Thomas M Grist; Bryan N Becker Journal: Am J Physiol Renal Physiol Date: 2006-10-24
Authors: Christian Ott; Rolf Janka; Axel Schmid; Stephanie Titze; Tilmann Ditting; Paul A Sobotka; Roland Veelken; Michael Uder; Roland E Schmieder Journal: Clin J Am Soc Nephrol Date: 2013-04-04 Impact factor: 8.237
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Felix Mahfoud; Christian Ukena; Roland E Schmieder; Bodo Cremers; Lars C Rump; Oliver Vonend; Joachim Weil; Martin Schmidt; Uta C Hoppe; Thomas Zeller; Axel Bauer; Christian Ott; Erwin Blessing; Paul A Sobotka; Henry Krum; Markus Schlaich; Murray Esler; Michael Böhm Journal: Circulation Date: 2013-06-18 Impact factor: 29.690
Authors: Henry Krum; Markus Schlaich; Rob Whitbourn; Paul A Sobotka; Jerzy Sadowski; Krzysztof Bartus; Boguslaw Kapelak; Anthony Walton; Horst Sievert; Suku Thambar; William T Abraham; Murray Esler Journal: Lancet Date: 2009-03-28 Impact factor: 79.321
Authors: Laima Siddiqi; Hans Hoogduin; Freddy Visser; Tim Leiner; Willem P Mali; Peter J Blankestijn Journal: J Clin Hypertens (Greenwich) Date: 2014-02-20 Impact factor: 3.738
Authors: Margreet F Sanders; Pieter Jan van Doormaal; Martine M A Beeftink; Michiel L Bots; Fadl Elmula M Fadl Elmula; Jesse Habets; Frank Hammer; Pavel Hoffmann; Lotte Jacobs; Patrick B Mark; Alexandre Persu; Jean Renkin; Giles Roditi; Wilko Spiering; Jan A Staessen; Alison H Taylor; Willemien L Verloop; Eva E Vink; Evert-Jan Vonken; Michiel Voskuil; Tim Leiner; Peter J Blankestijn Journal: Eur Radiol Date: 2017-03-07 Impact factor: 5.315
Authors: Pierre-Yves Courand; Helena Pereira; Costantino Del Giudice; Philippe Gosse; Matthieu Monge; Guillaume Bobrie; Pascal Delsart; Claire Mounier-Vehier; Pierre Lantelme; Thierry Denolle; Caroline Dourmap; Jean Michel Halimi; Xavier Girerd; Patrick Rossignol; Faiez Zannad; Olivier Ormezzano; Bernard Vaisse; Daniel Herpin; Jean Ribstein; Beatrice Bouhanick; Jean-Jacques Mourad; Emile Ferrari; Gilles Chatellier; Marc Sapoval; Arshid Azarine; Michel Azizi Journal: J Am Heart Assoc Date: 2017-10-10 Impact factor: 5.501